

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Patient-Oriented Research Review Committee.

Date: February 25–26, 2016.

Time: 8:30 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Stephanie Johnson Webb, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892, 301-435-0291, stephanie.webb@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 27, 2016.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-01816 Filed 2-1-16; 8:45 am]

BILLING CODE 4140-01-P

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; PPG Review for Transfusion.

Date: February 23, 2016.

Time: 8:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

Contact Person: Melissa E. Nagelin, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7202, Bethesda, MD 20892, 301-435-0297, nagelinmh2@nhlbi.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Methods for Measuring Tissue Oxygenation.

Date: February 25, 2016.

Time: 12:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, 301-435-0287, Pintuccig@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 27, 2016.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-01817 Filed 2-1-16; 8:45 am]

BILLING CODE 4140-01-P

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently HHS-certified laboratories and IITFs is published in the **Federal Register** during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at <http://www.samhsa.gov/workplace>.

FOR FURTHER INFORMATION CONTACT:

Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

HHS-Certified Instrumented Initial Testing Facilities

Dynacare, 6628 50th Street NW., Edmonton, AB Canada T6B 2N7, 780-784-1190 (Formerly: Gamma-Dynacare Medical Laboratories)

HHS-Certified Laboratories

ACM Medical Laboratory, Inc., 160 Elmgrove

Park, Rochester, NY 14624, 585-429-2264

Aegis Analytical Laboratories, Inc., 345 Hill

Ave., Nashville, TN 37210, 615-255-2400

(Formerly: Aegis Sciences Corporation,

Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories)

Alere Toxicology Services, 1111 Newton St.,

Gretna, LA 70053, 504-361-8989/800-

433-3823 (Formerly: Kroll Laboratory

Specialists, Inc., Laboratory Specialists,

Inc.)

Alere Toxicology Services, 450 Southlake

Blvd., Richmond, VA 23236, 804-378-

9130 (Formerly: Kroll Laboratory

Specialists, Inc., Scientific Testing

Laboratories, Inc.; Kroll Scientific Testing

Laboratories, Inc.)

Baptist Medical Center-Toxicology

Laboratory, 11401 I-30, Little Rock, AR

72209-7056, 501-202-2783 (Formerly:

Forensic Toxicology Laboratory Baptist

Medical Center)

Clinical Reference Lab, 8433 Quivira Road,

Lenexa, KS 66215-2802, 800-445-6917

DrugScan, Inc., 200 Precision Road, Suite

200, Horsham, PA 19044, 800-235-4890

Dynacare, * 245 Pall Mall Street, London,

ONT, Canada N6A 1P4, 519-679-1630

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS' NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (**Federal Register**, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the **Federal Register** on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

(Formerly: Gamma-Dynacare Medical Laboratories)

ElSohly Laboratories, Inc., 5 Industrial Park

Drive, Oxford, MS 38655, 662-236-2609

Fortes Laboratories, Inc., 25749 SW., Canyon

Creek Road, Suite 600, Wilsonville, OR

97070, 503-486-1023

Laboratory Corporation of America Holdings,

7207 N. Gessner Road, Houston, TX 77040,

713-856-8288/800-800-2387

Laboratory Corporation of America Holdings,

69 First Ave., Raritan, NJ 08869, 908-526-

2400/800-437-4986 (Formerly: Roche

Biomedical Laboratories, Inc.)

Laboratory Corporation of America Holdings,

1904 Alexander Drive, Research Triangle

Park, NC 27709, 919-572-6900/800-833-

3984 (Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem

Laboratories, Inc.; CompuChem

Laboratories, Inc., A Subsidiary of Roche

Biomedical Laboratory; Roche

CompuChem Laboratories, Inc., A Member

of the Roche Group)

Laboratory Corporation of America Holdings,

1120 Main Street, Southaven, MS 38671,

866-827-8042/800-233-6339 (Formerly:

LabCorp Occupational Testing Services,

Inc.; MedExpress/National Laboratory

Center)

LabOne, Inc. d/b/a Quest Diagnostics, 10101

Renner Blvd., Lenexa, KS 66219, 913-888-

3927/800-873-8845 (Formerly: Quest

Diagnostics Incorporated; LabOne, Inc.;

Center for Laboratory Services, a Division

of LabOne, Inc.)

MedTox Laboratories, Inc., 402 W. County

Road D, St. Paul, MN 55112, 651-636-

7466/800-832-3244

MetroLab-Legacy Laboratory Services, 1225

NE 2nd Ave., Portland, OR 97232, 503-

413-5295/800-950-5295

Minneapolis Veterans Affairs Medical Center,

Forensic Toxicology Laboratory, 1 Veterans

Drive, Minneapolis, MN 55417, 612-725-

2088, Testing for Veterans Affairs (VA)

Employees Only

National Toxicology Laboratories, Inc., 1100

California Ave., Bakersfield, CA 93304,

661-322-4250/800-350-3515

One Source Toxicology Laboratory, Inc., 1213

Genoa-Red Bluff, Pasadena, TX 77504,

888-747-3774 (Formerly: University of

Texas Medical Branch, Clinical Chemistry

Division; UTMB Pathology-Toxicology

Laboratory)

Pacific Toxicology Laboratories, 9348 DeSoto

Ave., Chatsworth, CA 91311, 800-328-

6942 (Formerly: Centinela Hospital Airport

Toxicology Laboratory)

Pathology Associates Medical Laboratories,

110 West Cliff Dr., Spokane, WA 99204,

509-755-8991/800-541-7891x7

Phamatech, Inc., 15175 Innovation Drive, San

Diego, CA 92128, 888-635-5840

Quest Diagnostics Incorporated, 1777

Montreal Circle, Tucker, GA 30084, 800-

729-6432 (Formerly: SmithKline Beecham

Clinical Laboratories; SmithKline Bio-

Science Laboratories)

Quest Diagnostics Incorporated, 400 Egypt

Road, Norristown, PA 19403, 610-631-

4600/877-642-2216 (Formerly: SmithKline

Beecham Clinical Laboratories; SmithKline

Bio-Science Laboratories)

Quest Diagnostics Incorporated, 8401

Fallbrook Ave., West Hills, CA 91304, 818-

737-6370 (Formerly: SmithKline Beecham

Clinical Laboratories)

Redwood Toxicology Laboratory, 3700650

Westwind Blvd., Santa Rosa, CA 95403,

800-255-2159

Southwest Laboratories, 4625 E. Cotton

Center Boulevard, Suite 177, Phoenix, AZ

85040, 602-438-8507/800-279-0027

STERLING Reference Laboratories, 2617 East

L Street, Tacoma, Washington 98421, 800-

442-0438

U.S. Army Forensic Toxicology Drug Testing

Laboratory, 2490 Wilson St., Fort George G.

Meade, MD 20755-5235, 301-677-7085,

Testing for Department of Defense (DoD)

Employees Only

Summer King,

Statistician.

[FR Doc. 2016-01819 Filed 2-1-16; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

[OMB Control Number 1615-0087]

Agency Information Collection Activities: Application for Citizenship and Issuance of Certificate Under Section 322, Form N-600K; Revision of a Currently Approved Collection

AGENCY: U.S. Citizenship and Immigration Services, Department of Homeland Security.

ACTION: 60-Day notice.

SUMMARY: The Department of Homeland Security (DHS), U.S. Citizenship and Immigration (USCIS) invites the general public and other Federal agencies to comment upon this proposed revision of a currently approved collection of information. In accordance with the Paperwork Reduction Act (PRA) of 1995, the information collection notice is published in the **Federal Register** to obtain comments regarding the nature of the information collection, the categories of respondents, the estimated burden (*i.e.* the time, effort, and resources used by the respondents to respond), the estimated cost to the respondent, and the actual information collection instruments.

DATES: Comments are encouraged and will be accepted for 60 days until April 4, 2016.

ADDRESSES: All submissions received must include the OMB Control Number 1615-0087 in the subject box, the agency name and Docket ID USCIS-2007-0019. To avoid duplicate submissions, please use only *one* of the following methods to submit comments:

(1) *Online.* Submit comments via the Federal eRulemaking Portal Web site at